1. ICAS: CTOS 2005 Review of Studies
U.S. NCI-funded Intergroup

2. ICAS: Mission and Vision
NCI-funded coalition of North American cooperative oncology groups with focus in Sarcoma Research
Leverage fixed infrastructures of SWOG, CALGB, ECOG, and NCI-Canada to advance publicly-funded sarcoma research

3. What is the Role of ICAS?
Differentiation of work from other smaller groups without NCI funding and with more restricted focus of activities
Where does national and international scale really need to be applied to advance research?

4. Strengths for Nationally Funded Sarcoma Research Effort
Very large scale effectiveness studies
Casting a very broad net to include the entire continent of physicians and patients
Legitamacy and stability of public sector funding through NCI

5. Review of ICAS Studies
S0033: randomized GIST testing Imatinib 400 v. 800
continuing molecular studies
survival long term
other sub-studies in progress

6. ICAS STUDIES Metastatic Disease
ICAS # Sarcoma Target Agent
S0330* MPNST EGF-R erlotinib
S0345 DFSP PDGF-R imatinib
S0346 Synovial HER trastuzumab
S0505 All STS VEGFR+ sorafenib
* First Stage accrual goal reached

7. ICAS STUDIES Metastatic Disease
ICAS # Sarcoma Target Inhibitor
S Chondro MTAP pemetrexed
S GIST KIT/PDGFR Imatinib
VEGF bevacizumab
S0416 (COG) GIST (Pedi-AYA) KIT/PDGFR imatinib

8. The Future of ICAS
Choose carefully which trials require full scope of national group mechanism
Optimize efficiency for participation through inclusive investigator registration mechanism
test the function and promise of the Clinical Trials Support Unit of NCI)

9. Patients with primary STS of the retroperitoneum or pelvis
Z9031
A randomized trial of preoperative radiation plus
surgery versus surgery alone for localized primary
retroperitoneal STS. P.W.T. Pisters, MD
Arm 1: Surgery
Patients with primary STS of the retroperitoneum or pelvis R A N D O M I Z E
Arm 2: XRT plus Surgery
CTSU !!!
A C O S O G

10. Complete Gross Resection
Z9001
Phase III randomized double-blind study of adjuvant Imatinib versus placebo in patients following resection of primary GIST. Study Coordinator: Ronald DeMatteo, MD
Primary GIST > 3 cm
Successful
Use of CTSU
Decentralized
Registrations
Complete Gross Resection
Tumor KIT +
Randomize
Placebo
x 1 yr
Imatinib
x 1 yr

11. ACOSOG in Development
Phase II evaluation of PET imaging as a predictor of response to neoadjuvant treatment for STS. Edward Cheng, MD (collaborative effort with ACRIN)
Neoadjuvant Rx
FDG-PET scan, routine staging studies
(MRI and CT)
Biopsy-
Confirmed
STS
Repeat FDG-PET
Wide local excision, histologic assessment of necrosis
A C O S O G